Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Dec 13, 2022
Trial Information
Current as of January 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to prevent and reduce the side effects of radiation therapy that can affect the esophagus, a condition known as radiation esophagitis. Researchers want to find out what symptoms patients experience during treatment and if there is any noticeable weight loss among participants. The goal is to improve comfort and health for those receiving thoracic radiation therapy.
To be eligible for the study, participants need to be 18 years or older and undergoing thoracic radiation with specific dosage criteria related to the esophagus. For instance, they must have a certain level of radiation exposure to the esophagus. However, individuals who cannot take a medication called Sucralfate, have a feeding tube, are taking opioid pain medications before starting radiation, or have a history of opioid use disorder are not eligible. If you participate, you can expect to share your experiences and symptoms during treatment, which will help researchers learn more about managing these side effects in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients being treated with thoracic irradiation with high-risk esophageal dose as determined below:
- Esophageal dose:
- • V50 ≥ 15% (25-35 once daily fractions) or 40 twice-daily \[BID\] fractions)
- • V40 ≥ 15% (15-24 once daily fractions or 30 twice-daily \[BID\] fractions)
- • V30 ≥ 15% (10-14 once daily fractions)
- • Age 18 years of age or older.
- Exclusion Criteria:
- • Known inability to take Sucralfate (tablet and/or suspension form), per physician discretion
- • PEG tube
- • Actively taking any opioid pain medications prior to radiation therapy
- • History of an opioid use disorder
Trial Officials
Jacob Shin, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
About Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Harrison, New York, United States
Middletown, New Jersey, United States
Montvale, New Jersey, United States
Uniondale, New York, United States
Commack, New York, United States
Basking Ridge, New Jersey, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials